🆕 HOW TO MAKE A #DIAGNOSIS OF #LUPUS ?!? is the most common question 🧐 I get ➡️ Well, certainly NOT ⛔ by checking ✔️ if you have at least 4 criteria 📑 on a list ! #SLE diagnosis is a complex process 👨‍🎓 and requires expertise. Ask your #rheumatologist 👍 if you are unsure 🏥.

✅ Major #DORIS meeting ongoing in Amsterdam with key worldwide #lupus experts, under the lead of Ronald van Vollenhoven, to refine the DORIS definition of #remission as the deeper DORIS+

✅ The American College of Rheumatology (ACR) officially released its updated Guideline for the Treatment of Systemic #Lupus Erythematosus (SLE) Link to FULL MANUSCRIPT: https://t.co/l71QWUL3wN

✅ Check my summary slide for the Phase 3 trial result of #Telitacicept (dual inhibitor of BLyS and APRIL) in systemic #lupus ⬇️ Link to the NEJM publication: https://t.co/AvUqKoKOkF

✅ The American College of Rheumatology (ACR) officially released its updated Guideline for the Treatment of Systemic #Lupus Erythematosus (SLE) Link to FULL MANUSCRIPT: https://t.co/l71QWUL3wN

✅ Thank you @LupusCanada 🙏

✅ What are the main differences between KDIGO, ACR and the recently published EULAR recommendations for #lupus #nephritis? Is combination therapy really becoming the new standard of care for ALL patients with LN? That's exactly what my today's talk in Portimao is about!

✅ Chicago 08:00am...this is the start of the 2025 Fall #SLICC group meeting, uniting worldwide collaborating clinics to move forward #Lupus care 👍

@G_O_Daniel 🌟 The study, co-led by first authors Dr @G_O_Daniel & Zoe Karakikla-Mitsakou (patient & General Secretary of Lupus Europe), with 🔝 Prof @LupusReference & @LenaKoskinalena, shows what’s possible when patients and doctors work together as equals 📚Read it https://t.co/uvWZg3YXHp

✅ The results of the phase 3 trial of #Telitacicept (dual inhibitor of BLyS and APRIL [a proliferation-inducing ligand]) in systemic #lupus have just been published in the NEJM (China-only trial)

🚨 #LUPUS TREATMENT ALERT The US FDA has approved #obinutuzumab for the treatment of Lupus #Nephritis Link to press release :

✅ Check my summary slide ⬇️ on the #obinutuzumab phase 3 (#REGENCY) trial in #lupus #nephritis 😉

🚨 #LUPUS TREATMENT ALERT The US FDA has approved #obinutuzumab for the treatment of Lupus #Nephritis Link to press release :

✅ Very happy to report that, together with an amazing group of #lupus experts and the help of @LupusEurope, we have reached the milestone where we now have the pilot version of the #lupus #brainfog severity scale (#LBFSS) 👍 and are now entering the validation phase

Muito obrigado 🇧🇷 🥹🙏

✅ Thank you very much @VillanderMarcus for the opportunity to discuss how we can improve the care of #lupus by solving together some of the (alas) too many challenges in #SLE

🎉Great chance to connect at the Bulgarian National Conference of Rheumatology 🇧🇬 ! ✅ Truly grateful for the opportunity to chair a Meet-the-Expert session with Prof. Laurent Arnaud, specially dedicated to young rheumatologists! 🙌 @EMEUNET @Lupusreference

✅ Real-world oral #glucocorticoid use in #SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database ➡️ FREE OPEN-ACCESS: https://t.co/cuUxbrIM4M

✅ Happy to discuss with the #Rheumatology colleagues of Bulgaria that no dose of glucocorticoids is safe or innocent in #Lupus. In our recent nation-wide study in France (~30 000 patients with #SLE) we detected that even mean GC doses 1-5mg/day were associated with complications

✅ Very grateful for the opportunity to meet the #Rheumatology colleagues from #Bulgaria at the Plovdiv 2025 national meeting 👍 #Challenges in #Lupus #MeettheProfessor session

#Comparative efficacy and safety of #anakinra and canakinumab ⬇️ in patients with #VEXAS syndrome - an international multicenter study https://t.co/tg7iWU2Afl